Table 6.
Epidemiology of ACTH deficit and other pituitary hormones deficit in primary and secondary hypophysitis
| Authors (Reference) | Etiology | Num of patients |
Age at diagnosis mean (ranges) |
Gender M/F (%) |
Frequency of pituitary hormones deficit | ||||
|---|---|---|---|---|---|---|---|---|---|
|
ACTH- deficit |
TSH- deficit |
FSH/LH- deficit |
GH- deficit |
AVP- deficit |
|||||
| Langlois et al. [80] | PAH | 3 | 57 yrs (30–73) | M: 33.3% F: 66.7% | 33.3% | N.A. | N.A. | N.A. | 66.7% |
| Angelousi et al. [85] | PAH | 22 | 41.9 yrs | M/F RATIO: 1/3.4 | 22.7% | 14% | 32% | 9% | 32% |
| Chiloiro et al. [86] | PAH | 21 | 40 yrs | M: 19% F: 80.9% | 33.3% | 14.3% | 42.8% | 23.8% | 47.6% |
| Felix Amereller et al. [87] | PAH | 60 | N.A. | M: 27% F: 73% | 67% | 57% | 52% | 20% | N.A. |
| Honegger et al. [88] | PAH | 76 | 41 yrs | M: 29% F 71% | 47% | 48% | 62% | 37% | 54% |
| Imber et al. [82] | PAH | 21 | 37.4 yrs | M: 38% F: 62% | 57% | 57% | 71.4% | 61.9% | 47.6% |
| Imga et al. [89] | PAH | 12 | 44 yrs (17–61) | M: 25% F 75% | 58% | 75% | 75% | 50% | 17% |
| Korkmaz et al. [84] | PAH | 17 | 31 | M:41.2% F:58.8% | 58.8% | 52.9% | 47.1% | 5.9% | 47.1% |
| Khare et al. [90] | PAH | 24 | N.A. | M: 12.5% F 87.5% | 75% | 58.3% | 50% | N.A. | 16.7% |
| Krishnappa et al. [91] | PAH | 39 | 34.9 | M/F RATIO 1: 4.6 | 64% | 56% | 54% | N.A. | 18% |
| Park et al. [81] | PAH | 22 | 48 yrs | M: 22.7% F: 77.3% | 36.3% | 36.3% | 31.8% | 22.7% | 81.8% |
| Oguz et al. [92] | PAH | 20 | 41.5 yrs | M: 25% F: 75% | 35% | 61% | 66% | 21% | 28% |
| Wang et al. [93] | PAH | 50 | 37.2 | M: 34% F: 66% | 26% | N.A. | 60% | 22% | 72% |
| Chiloiro et al. [97] | IIH | 9 | 59 yrs (41–83) | M: 66.7% F: 33.3% | 100% | 0% | 0% | 0% | 0% |
| Ryder et al. [98] | IIH | 19 | N.A. | M: 57.9% F: 42.1% | 84.2% | 57.9% | 38.5%a | N.A. | N.A. |
| Faje et al. [99] | IIH | 17 | 68.2 yrs | M: 88.2% F: 11.8% | 41.2% | 100% | 82.3% | N.A. | N.A. |
| Albarel et al. [100] | IIH | 15 | 55.5 yrs | M: 66.7% F: 33.3% | 73.3% | 86.7% | 80% | N.A. | N.A. |
| Le Min et al. [101] | IIH | 25 | N.A. | M: 76% F: 24% | 88% | 88% | 60% | 12% | N.A. |
| Scott et al. [102] | IIH | 11 | 67.8 | M: 65% F: 35% | 63.6% | 63.6% | 63.6% | N.A. | N.A. |
| Jessel et al. [103] | IIH | 69 | 64 (32–83) | M: 68.1% F: 31.9% | 68.1% | 34.8% | 75% | N.A. | N.A. |
| Kotwal et al. [104] | IIH | 26 | 57.9 | M: 54% F: 46% | 100% | N.A. | N.A. | N.A. | N.A. |
| Hong Chen et al. [105] | IIH | 28 | 61.2 | M: 57.1% F: 42.9% | 53.6% | 46.4% | N.A. | N.A. | N.A. |
N.A. data not available, M male, F female, ACTH AdrenoCorticoTropic Hormone, TSH Thyroid-Stimulating Hormone, FSH Follicle-Stimulating Hormone, LH Luteinizing Hormone, Yrs years, AVP Arginine VasoPressin, GH Growth Hormone
aEvaluated in 13 patients